Table 1.
Patient characteristics.
| Characteristics | Anti-HLA ab (non-DSA) | No anti-HLA ab n = 509 | P-value | |
|---|---|---|---|---|
| Shared TE-positive | Shared TE-negative | |||
| n = 40 | n = 29 | |||
| Donor | ||||
| Age, years, mean (SD) | 60.1 (9.3) | 60.2 (10.0) | 58.1 (10.1) | 0.24 |
| Female sex, n (%) | 28 (70) | 20 (69.0) | 336 (66.0) | 0.84 |
| Relationship, n (%) | 0.65 | |||
| Unrelated | 22 (55) | 12 (41.4) | 284 (55.8) | |
| Related (haplotype-unrelated) | 2 (5) | 2 (6.9) | 21 (4.1) | |
| Related (haplotype-related*) | 16 (40) | 15 (51.7) | 204 (40.1) | |
| Recipient | ||||
| Age, years, mean (SD) | 49.5 (18.2) | 49.0(12.8) | 47.6 (16.3) | 0.65 |
| Female sex, n (%) | 15 (37.5) | 13 (44.8) | 155 (30.5) | 0.19 |
| ABO-i, n (%) | 14 (35) | 9 (31.0) | 184 (36.1) | 0.85 |
| ESRD causes, n (%) | ||||
| Glomerulonephritis | 11 (27.5) | 11 (37.9) | 179 (35.2) | 0.58 |
| Polycystic kidney disease | 4 (10) | 1 (3.4) | 33 (6.5) | 0.54 |
| Diabetes | 10 (25) | 5 (17.2) | 116 (22.8) | 0.74 |
| Other | 15 (37.5) | 12 (41.4) | 181 (35.6) | 0.61 |
| Months on dialysis, n (%) | 0.47 | |||
| 0 (preemptive transplantation) | 18 (45) | 13 (44.8) | 272 (53.4) | |
| -6 | 4 (10) | 6 (20.7) | 66 (13.0) | |
| 6-47 | 10 (25) | 8 (27.6) | 108 (21.2) | |
| 48- | 8 (20) | 2 (6.9) | 63 (12.4) | |
| Pre-sensitizing event**, n (%) | 19 (47.5) | 14 (48.3) | 170 (33.4) | 0.06 |
| Pre-transplantation | 3 (7.5) | 0 (0) | 14 (2.8) | 0.15 |
| Pregnancy*** | 10 (66.7) | 11 (84.6) | 95 (61.3) | 0.24 |
| Transfusion | 10 (25) | 5 (17.2) | 96 (18.9) | 0.14 |
| Histocompatibility (HLA-A, B, DRB1/3/4/5, DQB1, DQA1), median (IQR) | ||||
| HLA mismatches | 6 (5 - 9) | 5 (5 – 9) | 6 (5 - 10) | 0.34 |
| HLAMatchmaker score | ||||
| AB | 11 (5 - 16) | 10 (4 – 16) | 12 (7 - 16) | 0.09 |
| DR | 8.5 (6 - 18) | 7 (4 – 14) | 11 (5 - 18) | 0.51 |
| DQ | 13.5 (5 - 23) | 12 (5 – 22) | 13 (7 – 22) | 0.92 |
| Total | 36 (24 – 49.5) | 29 (19 – 41) | 37 (25 – 51) | 0.30 |
| PIRCHE-II score | 184.5 (120 – 280.5) | 168 (112 - 260) | 199 (131 – 298) | 0.16 |
| Baseline immunosuppression at transplant, n (%) | ||||
| Steroid | 40 (100) | 29 (100) | 509 (100) | – |
| Tacrolimus | 24 (60) | 22 (75.9) | 338 (66.4) | 0.39 |
| Cyclosporin | 16 (40) | 7 (24.1) | 171 (33.6) | 0.39 |
| Everolimus | 8 (20) | 7 (24.1) | 103 (20.2) | 0.88 |
| Micophenolic acid | 31 (77.5) | 22 (75.9) | 400 (78.6) | 0.93 |
| Induction, n (%) | ||||
| Basiliximab | 40 (100) | 29 (100) | 509 (100) | – |
| Thymoglobulin | 0 (0) | 0 (0) | 0 (0) | – |
| Desensitization, n (%) | ||||
| Anti-CD20 therapy | 11 (27.5) | 7 (24.1) | 154 (30.3) | 0.74 |
| Plasmapheresis | 14 (35) | 9 (31.0) | 191 (37.5) | 0.75 |
| IVIG | 0 (0) | 0 (0) | 2 (0.4) | 0.87 |
*Haplotype-related donors shared one HLA haplotype with the recipients.
**Pre-sensitizing events were recorded as 1 per patient, even if the patient had multiple pre-sensitizing events.
***The percentage was calculated using only the female population.
Ab, antibody; non-DSA, non-donor-specific anti-HLA antibodies; TE, T cell epitope; SD, standard deviation; ABO-I, ABO-incompatible transplantation; ESRD, end stage renal disease; PIRCHE, predicted indirectly recognizable HLA epitopes; IVIG, intravenous immunoglobulin; HLA, human leukocyte antigen; IQR, interquartile range.